ChemPartner PharmaTech Co., Ltd. Class A

ChemPartner PharmaTech Co., Ltd. Class A

SSZSE:300149
8.08
CNY
-0.18
(-2.18%)
-0.01EPS
5.00BMarket Cap
ChemPartner PharmaTech Co., Ltd. Class A
SZSE:300149
(Shenzhen Stock Exchange)

Recent

price

8.08

P/E

ratio

- -

div

yld

0.06%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.4
0.4
0.58
0.6
0.76
0.75
0.6
0.67
2.17
2.68
2.97
3.4
2.67
2.28
1.93
2.54
2.59
Revenue per Share
0.11
0.07
0.09
0.09
0.11
0.14
0.15
0.14
0.35
0.28
0.31
-0.81
0.73
-1.84
-0.45
0.03
-0.01
Basic EPS, GAAP
0.01
-0.02
-0.17
-0.04
-0.05
0.18
0.14
0.14
0.29
-0.08
-0.1
0.19
-0.15
-0.1
0.2
0.29
- -
Free Cash Flow per Basic Share
0.02
0.02
0.02
0.02
0.03
0.03
0.05
0.05
0.1
0.16
0.11
0.16
0.08
0.01
0.01
0.01
- -
Dividend per Share
1.35
1.4
1.46
1.53
1.6
1.71
1.82
1.92
4.38
4.59
4.86
3.93
4.69
2.87
2.44
2.56
2.63
Book Value per Share
1.34
1.35
1.37
1.45
1.48
1.6
1.72
1.82
0.72
0.97
1.38
1.22
2.67
2.54
2.38
2.5
2.57
Tangible Book Value per Share
313
413
412
428
370
425
433
413
460
496
499
497
497
498
503
447
488
Basic Weighted Avg Shares
124
166
239
257
281
319
259
275
997
1,328
1,482
1,691
1,327
1,138
970
1,135
1,265
Sales/Revenue/Turnover
29.7
14.07
15.63
12.49
15.34
19.68
26.64
19.49
19.57
15.69
14.53
5.3
-4.63
-3.29
-4.41
3.45
3.8
Operating Margin (%)
4
6
9
17
21
22
20
20
66
101
105
194
193
140
132
117
- -
Depreciation Expense
34
28
35
40
41
59
65
58
161
139
155
-402
363
-917
-226
13
-7
Net Income, GAAP
14.26
13.95
17.15
16.24
11.85
13.82
15.1
13.77
10.25
5.58
20.4
- -
50.27
- -
- -
15.36
- -
Effective Tax Rate (%)
27.26
16.56
14.78
15.48
14.47
18.66
25.12
20.99
16.16
10.46
10.43
-23.79
27.34
-80.53
-23.34
1.18
-0.55
Profit Margin (%)
506
517
418
396
373
434
493
482
381
11
132
-303
548
300
297
410
427
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
580
612
792
1,185
672
501
374
334
319
LT Debt
571
611
641
670
697
724
770
835
2,205
2,303
2,452
1,989
2,370
1,461
1,238
1,300
1,359
Total Equity
8.78
4.74
5.44
5.02
5.79
8.35
8.43
7.59
8.64
4.15
4.62
- -
10.5
- -
- -
1.16
- -
Return on Invested Capital (%)
9.86
4.56
5.41
6.36
6.31
8.21
8.71
7.51
10.32
6.18
5.69
- -
11.2
- -
- -
1.52
- -
Return on Capital (%)
10.04
4.74
5.85
6.29
6.16
8.5
8.7
7.31
10.73
6.2
6.55
-18.32
16.83
-48.48
-17.09
1.08
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
134
127
169
LT Borrowings
29
24
24
LT Finance Leases
288
272
295
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
498
498
505
Market Capitalization
5,154
4,751
4,999

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
789
756
859
Cash, Cash Equivalents & STI
465
408
440
Accounts Receivable, Net
240
252
292
Inventories
17
18
17
Total Current Liabilities
370
346
432
Payables & Accruals
- -
- -
- -
ST Debt
134
127
169
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.14%
-9.66%
5.03%
Free Cash Flow
-75.67%
-152.08%
29.37%
Net Income, GAAP
-91.01%
-216.89%
-105.92%
Sales/Revenue/Turnover
27.5%
-3.89%
16.96%
Total Cash Common Dividend
8.47%
-29.63%
0.86%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
235
231
253
252
970
2025
261
273
- -
318
1,135
2026
267
296
385
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.05
-0.08
- -
-0.33
-0.45
2025
0.01
0.04
- -
0.01
0.03
2026
-0.04
-0.03
0.04
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -
Business
ChemPartner PharmaTech Co., Ltd. is a contract research and contract development and manufacturing organization (CRO/CDMO) that provides integrated drug discovery, preclinical development, and biomanufacturing services to biotechnology and pharmaceutical companies worldwide. Founded in 2000 and headquartered in Shanghai, China, the company operates across two principal business divisions: Drug Discovery & Preclinical Research Services, and Biopharmaceutical Development & Manufacturing Services. Its comprehensive portfolio includes Discovery Chemistry, encompassing synthetic and medicinal chemistry, computer-aided drug design, compound library synthesis, and active pharmaceutical ingredient synthesis; Biologics Discovery, comprising antibody generation, hybridoma technology, phage display, single B-cell cloning, antibody engineering, and recombinant protein production; In Vitro Biology and In Vivo Pharmacology, providing target validation, high-throughput screening, enzymatic and cell-based assays, disease-specific animal models in oncology, immunology, and metabolic disorders, as well as exploratory toxicology; Drug Metabolism and Pharmacokinetics (DMPK), offering in vitro ADME profiling, in vivo pharmacokinetic/pharmacodynamic modeling, and bioanalytical testing; and CDMO Solutions, delivering cell line development, microbial fermentation, mammalian cell culture bioprocessing, analytical formulation development, and cGMP-compliant clinical and commercial manufacturing for biologics and small molecules. ChemPartner PharmaTech serves multinational pharmaceutical corporations, emerging biotech innovators, and life science research institutes across North America, Europe, China, and the broader Asia-Pacific region, operating major laboratory and production complexes in Shanghai, Chengdu, and Qidong, alongside commercial and technical support operations in South San Francisco, California. In recent strategic developments, the company finalized the divestiture of its legacy microecological nutrition business to establish itself as a dedicated, pure-play biopharmaceutical CRO/CDMO; accelerated the expansion of advanced therapeutic platforms, including antibody-drug conjugates (ADCs), targeted protein degradation (PROTACs), and complex peptide synthesis; upgraded its cGMP biologics manufacturing facilities to comply with FDA, EMA, and NMPA standards; and restructured its international business development framework to broaden strategic collaborations with global drug developers.